OWC Pharmaceutical Research Corp.

 

Dr. Stanley Hirsch – Chairman

Dr. Hirsch joined OWCP as Chairman of our Board of Directors in July 2017. He has had extensive scientific, executive and board level experience for more than 25 years in private and publicly listed companies in biopharmaceutical and agricultural biotech industries, inter alia, including direct experience in raising capital and leading M&A activity. This experience, together with his multi-cultural management skills, having managed companies in IsraelBrazil, UK, China and the United States, is directly relevant to OWCP’s scientific and business development efforts.

Dr. Hirsch has served as Group CEO of FuturaGene Limited and its predecessor company, FuturaGene Plc., since 2007. He has also served as Chairman of the Board of Directors of Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), since 2016. and

Dr. Hirsch holds a D. Phil (1982) in Cell Biology and Immunology from Oxford University, UK. His educational experience also includes a B.Sc. degree with Honors in Medical Biochemistry from the University of Cape Town, South Africa (1979) among other academic honors and awards from Oxford University and University of Cape Town. 

 

Mr. Mordechai Bignitz – Chief Executive Officer (CEO)

motiMr. Mordechai Bignitz is a seasoned financial manager, with over 30 years’ experience in operational and investment management, specializing in all aspects of the planning and execution of deals in private and public companies. Mr. Bignitz served as CEO of Geffen Green Energy Ltd. and as a director of Leader Capital Markets Ltd. (TASE: LDRC) and Leader Holdings & Investments Ltd. (TASE: LDER). He has extensive experience in the management of investments and financial systems, accounting and taxation and has been involved in economic and financial consulting to companies in the field of technology.

Mr. Bignitz is a CPA, with a BA in Accounting and Economics from Tel-Aviv University and completed the Executive Program in Management and Strategy in Retail at Babson College in Boston.

 

Mr. Yossi Dagan, CPA (IL) – Chief Financial Officer (CFO)

Mr. Yossi Dagan has extensive experience with Nasdaq-listed companies in various industries and provides financial, capital markets, accounting and regulatory expertiseto OWCP.

Mr. Dagan has served as CFO of Top Image Systems Ltd. (NASDAQ: TISO), since 2015. TISA is a global company with operations  in the USA, Israel, Germany, UK, Singapore, Japan and Brazil. Mr. Dagan previously served as VP of Finance at Kenshoo – an Israeli based global SaaS company employing 600 employees, as Corporate Controller at Imperva Inc. – a leading provider of cyber security solutions that protect business-critical data and applications, and as a manager at PriceWaterhouseCoopers.

Mr. Dagan is a CPA with a BA in Accounting and Business from The College of Management, Rishon Le’Zion, Israel.

 

Mr. Jeffrey Friedland – Advisory Board Member 

Mr. Jeffrey Friedland is an emerging markets pioneer. Friedland Global Capital Pte. Ltd. was one of the first American investment banks to establish a presence in China. Mr. Friedland , has been at the forefront of the global cannabis industry as an investor as well as business owner.

In his book “Marijuana: The World’s Most Misunderstood Plant”, Mr. Friedland examines the world of medical marijuana, discussing the plant’s history, what we know about the plant and its undeveloped potential.  Mr. Friedland has been a frequent speaker at conferences and events dealing with individual and institutional investors on investments, emerging markets, and the global cannabis industry.

 

Ms. Miriam (Miri) Sani, M.Sc Eng. – Advisory Board Member

Ms. Miri Sani holds an M.Sc. in Chemistry from the Technion – Israel Institute of Technology, Haifa, Israel.

Ms. Sani is the CEO and owner of “Shefa Amirim” Ltd, which provides regulatory affairs and clinical consultation services for early-stage start-ups in various medical fields. During the past five years, Ms. Sani has shepherded various projects and treatments in the areas of dermatology, proctology, cardio-vascular, ophthalmology, urology, cell therapy, OB-GYN and IVD’s through both clinical studies and regulatory affairs.

Ms. Sani  will advise OWCP on the transition of its innovatively-developed cannabinoid products and delivery systems to full industrial and commercial production She will supervise  regulatory compliance with applicable healthcare agencies and ministries. Ms. Sani will also supervise protocol and quality compliance at manufacturing facilities of OWCP third party licensees.

 

Dr. Sharon Rozenblat – Advisory Board Member

Dr. Sharon Rozenblat is tasked with overseeing the completion of the pre-clinical safety studies on the Company’s treatment for psoriasis, which commenced in November 2016. Dr. Rozenblat will also steer the Company’s efforts to commercialize its cannabis-based formulations and delivery mechanisms.

Ms. Rozenblat earned her Ph.D. in biochemistry and cell biology (Magna Cum Laude) from Bar-Ilan University in Israel. Her research focused on botanical components for Melanoma (skin cancer) treatment. From 2007 to 2015, Dr. Rozenblat served as Chief Scientist at Kamedis ltd., an Israeli-based dermatological company, where she had established and managed the research and development of herbal products for the treatment of dermatological conditions.

Dr. Rozenblat was also the Scientific Director for the development of herbal extraction in a joint venture with Green Mountain Biotech (GMB), in Chengdu, China, where she worked with GMB to find agricultural resources, develop extraction methods, establish quality control methodologies, and conduct safety and efficacy studies.

Dr. Rozenblat serves as a consultant to international organizations, including as Scientific Research Director of joint development projects funded by the Korea-Israel Industrial Research and Development Foundation (KORIL), and the Israel-Singapore Foundation (SIIRD), both of which resulted in numerous products and patents.

 

 


 

One World Cannabis Ltd.

 

Mr. Mordechai Bignitz – Chief Executive Officer (CEO)

moti

Mr. Mordechai Bignitz is a seasoned financial manager, with over 30 years’ experience in operational and investment management, specializing in all aspects of the planning and execution of deals in private and public companies. Mr. Bignitz served as CEO of Geffen Green Energy Ltd. and as a director of Leader Capital Markets Ltd. (TASE: LDRC) and Leader Holdings & Investments Ltd. (TASE: LDER). He has extensive experience in the management of investments and financial systems, accounting and taxation and has been involved in economic and financial consulting to companies in the field of technology.

Mr. Bignitz is a CPA, with a BA in Accounting and Economics from Tel-Aviv University and completed the Executive Program in Management and Strategy in Retail at Babson College in Boston.

 

Mr. Alon Sinai – Chief Operating Officer (COO)

img_6330-273x300Mr. Alon Sinai is a retired Lieutenant-Colonel from the Medical Corps of IDF (1987-2013), and completed the NATO School Oberammergau program (NATO’s premier individual training and education facility at the operational level). Most recently he served as Head of the Doctrine, Instruction and Training Department, where he was responsible for commanding and developing emergency medical facilities, writing professional doctrine and literature for the IDF Medical Corps and working with foreign militaries.

Mr. Sinai is currently pursuing his Ph.D. in Health Systems Management at Ben-Gurion University of the Negev, where he previously earned an MA in Health Systems Management and a B.EMS in Emergency Medicine.

 

Dr. Med. Yehuda Baruch – Director of Research and Regulatory Affairs 

img_63-255x300Dr. Yehuda Baruch served as Head of the Israeli Ministry of Health’s Medical Marijuana Program from 2003 through 2013 where he spearheaded the efforts on regulation, chaired the indication committee, secured Helsinki Approvals for medical research, and managed regulation of patient licensing and dosage. He has extensive experience in researching medical cannabis, most notably for its effect on PTSD.

From 2004 until recently he served as CEO of Abarbanel Mental Health Center in Bat Yam, Israel. Prior to that, he was the director of Israel’s Ministry of Health medical management division, and director general of Be’er Yakov Mental Health Center. He has taught at Ben-Gurion University of the Negev and Tel Aviv University’s Sackler School of Medicine.

 

Mr. Yossi Dagan, CPA (IL) – Chief Financial Officer (CFO)

Mr. Yossi Dagan has extensive experience with Nasdaq-listed companies in various industries and provides financial, capital markets, accounting and regulatory expertiseto OWCP.

Mr. Dagan has served as CFO of Top Image Systems Ltd. (NASDAQ: TISO), since 2015. TISA is a global company with operations  in the USA, Israel, Germany, UK, Singapore, Japan and Brazil. Mr. Dagan previously served as VP of Finance at Kenshoo – an Israeli based global SaaS company employing 600 employees, as Corporate Controller at Imperva Inc. – a leading provider of cyber security solutions that protect business-critical data and applications, and as a manager at PriceWaterhouseCoopers.

Mr. Dagan is a CPA with a BA in Accounting and Business from The College of Management, Rishon Le’Zion, Israel.